04:33 AM EDT, 09/12/2025 (MT Newswires) -- Avidity Biosciences ( RNA ) said Thursday it has priced a public offering of 15 million shares at $40 apiece for expected gross proceeds of $600 million.

Underwriters have been granted a 30-day option to purchase up to 2.3 million additional shares.

The offering, which is expected to close around Monday, has been upsized from the initial $500 million.

Avidity said it intends to use net proceeds of the offering, along with existing cash and equivalents, to advance its clinical programs, build up inventory, and for general corporate purposes.